InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD 42.06
-1.44 (-3.31%)
Jul 30, 2026, 4:08 PM HKT
HKG:3696 Revenue
In the year 2025, InSilico Medicine Cayman TopCo had annual revenue of $56.24M USD, down -34.48%. InSilico Medicine Cayman TopCo had revenue of $28.78M in the half year ending December 31, 2025.
Revenue
$56.24M
Revenue Growth
-34.48%
P/S Ratio
55.00
Revenue / Employee
$177.41K
Employees
317
Market Cap
24.08B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.24M | -29.60M | -34.48% |
| Dec 31, 2024 | 85.83M | 34.65M | 67.71% |
| Dec 31, 2023 | 51.18M | 21.03M | 69.77% |
| Dec 31, 2022 | 30.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionInSilico Medicine Cayman TopCo News
- 3 days ago - Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors - PRNewsWire
- 7 days ago - AI shortens drug discovery to around 1 year in China, Insilico CEO says - Reuters
- 15 days ago - Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine - Reuters
- 17 days ago - China Medical System to pay Insilico up to $177 million for nervous system work - Reuters
- 17 days ago - Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases - PRNewsWire
- 21 days ago - Insilico Jumps On H1 Profit Forecast, Advances AI-Leveraged Rentosertib To Phase III Trial In IPF - Nasdaq
- 21 days ago - Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 - PRNewsWire
- 4 weeks ago - Insilico Medicine Announces Strategic AI Drug Discovery Collaboration With Takeda - Nasdaq